Abstract
As healthcare costs are rising globally and biologic treatments are a growing segment of the cost, governments have created biosimilar regulatory pathways in attempt to lower the costs of biologics. Since biosimilars are still relatively nascent, the impact of the biosimilars from a practical and academic viewpoint is emerging. This research begins to fill a current gap in the literature, quantitatively evaluating the drivers that firms face regarding entering into the biosimilars market. Further, this research contributes to the practical and academic understanding of process innovation by presenting the biosimilar phenomenon and the competitive dynamics of biosimilar market entry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
